Email Page Print Page

SEC Filings and Financial Information

NASDAQBDSI
FormDescriptionDateFormat
CT ORDERConfidential treatment orderSep 5, 2017View HTMLDownload DOCDownload PDF
CT ORDERConfidential treatment orderMar 27, 2017View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2017View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2017View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GFeb 13, 2017View HTMLDownload DOCDownload PDFDownload XLS
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsFeb 10, 2017View HTMLDownload DOCDownload PDFDownload XLS
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsJan 13, 2017View HTMLDownload DOCDownload PDFDownload XLS
Top News
Oct 12, 2017

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that it has entered into a...

Oct 6, 2017

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) participated in a round table meeting convened this week in Washington, D.C. by the U.S. Department of Health and Human Services (HHS) to...

Sep 19, 2017

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, Vice Chairman, President and Chief Executive Officer, will present at two upcoming healthcare conferences....

investor inquiries

 

Al Medwar
Senior Vice President, Corporate and Business Development
BioDelivery Sciences International, Inc.
919-582-9050
amedwar@bdsi.com